Healthy volunteers help uncover drug interactions for new compound

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study. * Age 18 to 55 years, inclusive, at the time of signing the ICF. * Body mass index between 18.0 and 32.0 kg/m2 (inclusive). * Willingness to adhere to study-related prohibitions, restrictions, and procedures. * Ability to swallow and retain PO medication. * Willingness to avoid pregnancy or fathering children based on the criteria defined in the prootcol. Exclusion Criteria: * History of uncontrolled or unstable cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening. * History of rheumatologic/autoimmune disorders and immune deficiency/immunologic defects. * History of major bleeding or thrombosis, including myocardial infarction/stroke and pulmonary embolism/deep vein thrombosis. * Known tuberculosis infection that is active or participant-reported history of tuberculosis or treatment thereof. * Resting pulse \< 40 bpm or \> 100 bpm, confirmed by repeat testing at screening. * Presence of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis). * Any major surgery within 12 weeks of screening. * Positive test for hepatitis B virus, hepatitis C virus, or HIV. Note: Participants whose results are compatible with prior immunization or immunity due to infection for hepatitis B may be included at the discretion of the investigator. * Positive urine or breath test for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet. * Use of tobacco- or nicotine-containing products within 1 month of screening. * Women who are pregnant or breastfeeding. * eGFR \< 90 mL/min/1.73 m2 based on the CKD-EPI equation. * Any history of hypersensitivity or intolerance to itraconazole, rifampin, esomeprazole or any other PPI, or famotidine or any other H2 antagonist. Other protocol-defined Inclusion/Exclusion Criteria may apply.